» Articles » PMID: 4359938

Direct Inhibitory Effect of Hypercalcemia on Renal Actions of Parathyroid Hormone

Overview
Journal J Clin Invest
Specialty General Medicine
Date 1974 Mar 1
PMID 4359938
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of calcium on the renal actions of parathyroid hormone (PTH) were studied in vivo and in vitro. In parathyroidectomized rats, variable levels of blood calcium concentration were induced by intravenous infusion of calcium. The renal responses to the injected PTH, i.e. phosphate and cyclic AMP excretion, were compared in these animals. After PTH injection, the increases of both phosphate and cyclic AMP excretion were less in the calcium-infused animals than in the control group without calcium infusion. There was an inverse correlation between the renal responses to PTH and plasma calcium concentration of 4.2-13.5 mg/100 ml. But calcium had no effect on phosphate excretion induced by infusion of dibutyryl cyclic AMP. In the in vitro experiments, the increase of cyclic AMP concentration in response to PTH was less in renal cortical slices taken from the calcium-infused animals than in ones from the control group without calcium infusion. Calcium also inhibited the activation of renal cortical adenylate cyclase in response to PTH, but calcium had no effect on phosphodiesterase. The data indicate that calcium directly inhibits renal actions of PTH both in vivo and in vitro. Such inhibitory mechanism is probably at or before the step of PTH-dependent cyclic AMP generation in the kidney.

Citing Articles

Inhibition of renal adenylate cyclase by plasma from uremic patients.

Juppner H, Hesch R J Endocrinol Invest. 1982; 5(5):303-9.

PMID: 7153474 DOI: 10.1007/BF03350518.


Rapid development of renal resistance to low doses of synthetic bovine parathyroid hormone fragment 1-34. Dissociation of urinary cyclic adenosine monophosphate, phosphaturic, and calciuric responses.

Law Jr W, Heath 3rd H J Clin Invest. 1983; 72(3):1106-13.

PMID: 6309905 PMC: 1129278. DOI: 10.1172/JCI111035.


Renal refractoriness to PTH in experimental Fanconi syndrome: evidence for intact adenylate cyclase activation.

Wald H, Popovtzer M Pflugers Arch. 1984; 402(1):116-9.

PMID: 6095175 DOI: 10.1007/BF00584840.


Pathogenic role of cyclic AMP in the impairment of urinary concentrating ability in acute hypercalcemia.

Beck N, Singh H, Reed S, MURDAUGH H, Davis B J Clin Invest. 1974; 54(5):1049-55.

PMID: 4371361 PMC: 301652. DOI: 10.1172/JCI107848.


Familial hypocalciuric hypercalcaemia--familial benign hypercalcaemia: a review.

Auwerx J, Brunzell J, Bouillon R, Demedts M Postgrad Med J. 1987; 63(744):835-40.

PMID: 3328847 PMC: 2428623. DOI: 10.1136/pgmj.63.744.835.


References
1.
CHASE L, Aurbach G . Renal adenyl cyclase: anatomically separate sites for parathyroid hormone and vasopressin. Science. 1968; 159(3814):545-7. DOI: 10.1126/science.159.3814.545. View

2.
CHASE L, Aurbach G . Parathyroid function and the renal excretion of 3'5'-adenylic acid. Proc Natl Acad Sci U S A. 1967; 58(2):518-25. PMC: 335666. DOI: 10.1073/pnas.58.2.518. View

3.
Cheung W . Properties of cyclic 3',5'-nucleotide phosphodiesterase from rat brain. Biochemistry. 1967; 6(4):1079-87. DOI: 10.1021/bi00856a017. View

4.
Agus Z, Puschett J, SENESKY D, Goldberg M . Mode of action of parathyroid hormone and cyclic adenosine 3',5'-monophosphate on renal tubular phosphate reabsorption in the dog. J Clin Invest. 1971; 50(3):617-26. PMC: 291970. DOI: 10.1172/JCI106532. View

5.
Kaneko T, Field J . A method for determination of 3',5'-cyclic adenosine monophosphate based on adenosine triphosphate formation. J Lab Clin Med. 1969; 74(4):682-90. View